Literature DB >> 32389785

Comparison of CRB-65 and quick sepsis-related organ failure assessment for predicting the need for intensive respiratory or vasopressor support in patients with COVID-19.

Ying Su1, Guo-Wei Tu2, Min-Jie Ju3, Shen-Ji Yu4, Ji-Li Zheng5, Guo-Guang Ma6, Kai Liu7, Jie-Fei Ma8, Kai-Huan Yu9, Yuan Xue10, Zhe Luo11.   

Abstract

Entities:  

Keywords:  COVID-19; CRB-65; CURB-65; Community-acquired pneumonia; qSOFA

Mesh:

Year:  2020        PMID: 32389785      PMCID: PMC7204730          DOI: 10.1016/j.jinf.2020.05.007

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


× No keyword cloud information.
Dear Editor, We read the recent published paper by Chen and colleagues in journal of Infection with great interest, which described the clinical progression of patients with COVID-19 in Shanghai, China. Since December 2019, an outbreak of coronavirus disease 2019 (COVID-19) emerged in Wuhan, China and spread globally to become a public health emergency of international concern. Patients with COVID-19 tend to progress after onset of symptoms within 7 days and severe type may rapidly progress to acute respiratory distress syndrome (ARDS) or end-organ failure. , Therefore, early and simple identification of patients who require intensive respiratory or vasopressor support (IRVS) would be of considerable value during the outbreak of the COVID-19 crisis. Thus far, there are no effective severity assessment tools for patients with COVID-19. Here, we performed a retrospective single-center study to compare the performance of simple score systems such as quick sepsis-related organ failure assessment (qSOFA), the CURB-65 score adopted by the British Thoracic Society, and its simpler versions (CRB and CRB-65) to predict the need for IRVS in patients with COVID-2019. Patients with confirmed COVID-19 and age ≥18 years hospitalized between February 7, 2020 and February 17, 2020 in Renmin Hospital of Wuhan University were screened in this study. Patients were excluded if they died within 48 h of admission, were pregnant, or had a Do Not Resuscitate (DNR) order. Baseline demographics, co-morbidities, clinical symptoms or signs, vital signs, laboratory results on admission, and outcomes were collected. The CRB, CRB-65, CURB-65 and qSOFA scores were calculated on basis of demographic and clinical characteristics of each patient. A total of 116 patients were eventually included for this study. The baseline characteristics are presented in Table 1 . The median age of this cohort was 63[IQR 51 to 72] and 47.4% patients were males. The most common symptom was fever (86.2%), followed by fatigue (85.3%) and cough (69.0%). On admission, the median scores of CRB, CRB-65, CURB-65, and qSOFA were 0[0,1], [0,1], 1[0,2] and 1[0,1], respectively. A total of 25 (21.6%) patients needed IRVS during the period of hospital stay. Patients with IRVS had higher CRB (1[0,2] vs. 0[0,0], P<0.001), CRB-65 (2[1,3] vs. 1[0,1], P<0.001), CURB-65 (3[2,3] vs. 1[0,1], P<0.001), and qSOFA scores (1[1,2] vs. 1[0,1], P=0.001) than non-IRVS patients. The hospital mortality rate in this cohort was 7.8%. The median length of hospital stay was 29 [18,36] days.
Table 1

Clinical characteristics of COVID-19 patients.

Entire cohortNo need for IRVSNeed for IRVSP value
Number of patients1169125
Age (years)63[51, 72]61[48,69]72[63,81]<0.001
Gender (male), n (%)55(47.4)42(46.2)13(52)0.66
Smoking history, n (%)10(8.6)9(9.9)1(4)0.69
Comorbidities
Hypertension, n (%)38(32.8)25(27.5)13(52)0.03
Diabetes mellitus, n (%)20(17.2)15(16.5)5(20)0.77
CAD, n (%)12(10.3)9(9.9)3(12)0.72
COPD, n (%)2(1.7)0(0)2(8)0.05
Cerebrovascular disease, n (%)2(1.7)1(1.1)1(4)0.39
Chronic renal disease, n (%)4(3.4)3(3.3)1(4)1.00
Signs and symptoms
Fever, n (%)100(86.2)76(83.6)24(96)0.19
Cough, n (%)80(69.0)62(68.1)18(72)0.81
Sputum production, n (%)15(12.9)11(12.1)4(16)0.74
Fatigue, n (%)99(85.3)76(83.5)23(92)0.36
Headache, n (%)6(5.2)6(6.6)0(0)0.34
Dyspnea, n (%)66(56.9)44(48.4)22(88)<0.001
Nausea or vomiting, n (%)25(21.6)18(19.8)7(28)0.41
Diarrhea, n (%)23(19.8)18(19.8)5(20)1.00
Anorexia, n (%)8(6.9)2(2.2)6(24)0.001
Myalgia or arthralgia, n (%)10(8.6)8(8.8)2(8)1.00
Onset of symptom to hospital admission12[9,16]12[9,17]10[7,16]0.08
Vital signs at hospital admission
Altered mental status, n (%)6(5.2)0(0)6(24)<0.001
Heart rate, beats/minute90[79, 102]86[78,100]96[86,107]0.02
Respiratory rate, breaths/minute23[20,29]22[20,25]32[22,35]<0.001
Systolic blood pressure, mm Hg132[122,145]131[122, 144]137[121,152]0.38
Diastolic blood pressure, mm Hg78[68,84]79[69,84]74[66,91]0.98
Severity of illness scores at hospital admission
CRB0[0,1]0[0,0]1[0,2]<0.001
CRB-651[0,1]1[0,1]2[1,3]<0.001
CURB-651[0,2]1[0,1]3[2,3]<0.001
qSOFA1[0,1]1[0,1]1[1,2]0.001
Blood urea nitrogen, mmol/L4.85[3.91, 6.30]4.67[3.69,5.84]7.35[4.85,9.28]<0.001
Respiratory support
High flow nasal cannula, n (%)24(20.7)0(0)24(96)<0.001
Non-invasive mechanical ventilation, n (%)5(4.3)0(0)5(20)<0.001
Invasive mechanical ventilation, n (%)8(6.9)0(0)8(32)<0.001
Renal replacement therapy, n (%)3(2.6)2(2.2)1(4)0.52
Extracorporeal membrane oxygenation, n (%)1(0.9)0(0)1(4)0.22
Need for vasopressor support, n (%)9(7.8)0(0)9(36)<0.001
Need for IRVS, n (%)25(21.6)0(0)25(100)<0.001
Hospital mortality, n (%)9(7.8)0(0)9(36)<0.001
Hospital length of stay, days29[18,36]28[18,33]38[8,49]0.18

Continuous variables are shown as the mean ± SD or median [IQR], as appropriate. Categorical variables are shown as number (%).

COVID-19, coronavirus disease 2019; BUN, blood urea nitrogen; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; CRB, confusion, respiratory rate, and blood pressure; CRB-65, confusion, respiratory rate, blood pressure and age ≥65 years; CURB-65, confusion, urea nitrogen, respiratory rate, blood pressure and age ≥65 years; SOFA, Sepsis-related Organ Failure Assessment; qSOFA, quick Sepsis-related Organ Failure Assessment; IRVS, intensive respiratory or vasopressor support.

Clinical characteristics of COVID-19 patients. Continuous variables are shown as the mean ± SD or median [IQR], as appropriate. Categorical variables are shown as number (%). COVID-19, coronavirus disease 2019; BUN, blood urea nitrogen; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; CRB, confusion, respiratory rate, and blood pressure; CRB-65, confusion, respiratory rate, blood pressure and age ≥65 years; CURB-65, confusion, urea nitrogen, respiratory rate, blood pressure and age ≥65 years; SOFA, Sepsis-related Organ Failure Assessment; qSOFA, quick Sepsis-related Organ Failure Assessment; IRVS, intensive respiratory or vasopressor support. ROC curve analyses were performed to evaluate the performance of four simple score systems to predict the need for IRVS. The AUC, optimal cut-off value, sensitivity, specificity, and positive and negative predictive values of each score system were shown in Table 2 . The optimal cut-off score of CRB-65 for prediction of IRVS was 2, which provided sensitivity of 64% and specificity of 93.4%. The AUC values of the CRB-65 score in predicting the need for IRVS were much higher than those for the qSOFA score (0.81 ± 0.05 vs. 0.70 ± 0.06, P=0.02). The CRB-65 had higher AUC values than CRB score for IRVS prediction, however, the difference was not statistically significant (0.81 ± 0.05 vs. 0.77 ± 0.05, P=0.22). The AUC values were comparable between CRB-65 and CURB-65 for IRVS prediction (0.81 ± 0.05 vs. 0.85 ± 0.05, P=0.08).
Table 2

Performance of variables in predicting clinical outcomes.

OutcomesPredictorsAU ROC95% CIPCut-offSensitivity (%)Specificity (%)PPVNPVLR+LR-
Need for IRVSCRB0.77 ± 0.050.69-0.85<0.00117279.148.691.13.450.35
CRB22896.770838.490.74
CRB-650.81 ± 0.050.73-0.88<0.00118845.130.693.21.60.27
CRB-6526493.472.790.49.710.39
CRB-6532497.87582.410.920.78
CURB-650.85 ± 0.050.77-0.91<0.00118842.929.792.91.540.28
CURB-6528087.964.594.16.620.23
CURB-6535296.781.28815.770.5
CURB-6541298.97580.410.920.89
qSOFA0.70 ± 0.060.60-0.78<0.00118047.329.489.61.520.42
qSOFA22498.985.782.621.840.77

Abbreviations: AUROC, area under the receiver operating characteristic curve; CI, confidence interval; LR, likelihood ratio; PPV, positive predictive values; NPV, negative predictive value; CRB, confusion, respiratory rate, and blood pressure; CRB-65, confusion, respiratory rate, blood pressure and age ≥65 years; CURB-65, confusion, urea nitrogen, respiratory rate, blood pressure and age ≥65 years; qSOFA, quick Sepsis-related Organ Failure Assessment; IRVS, intensive respiratory or vasopressor support. Bold: the optimal cut-off values according to Youden index.

AUC comparisons

CRB-65 vs. qSOFA, P=0.02; CRB-65 vs. CRB, P=0.22; CRB-65 vs. CURB-65, P=0.08; CRB vs. qSOFA, P=0.09.

Performance of variables in predicting clinical outcomes. Abbreviations: AUROC, area under the receiver operating characteristic curve; CI, confidence interval; LR, likelihood ratio; PPV, positive predictive values; NPV, negative predictive value; CRB, confusion, respiratory rate, and blood pressure; CRB-65, confusion, respiratory rate, blood pressure and age ≥65 years; CURB-65, confusion, urea nitrogen, respiratory rate, blood pressure and age ≥65 years; qSOFA, quick Sepsis-related Organ Failure Assessment; IRVS, intensive respiratory or vasopressor support. Bold: the optimal cut-off values according to Youden index. AUC comparisons CRB-65 vs. qSOFA, P=0.02; CRB-65 vs. CRB, P=0.22; CRB-65 vs. CURB-65, P=0.08; CRB vs. qSOFA, P=0.09. To the best of our knowledge, the present study is the first to investigate the predictive performance of simple score systems in patients with COVID-19. In this study, the CRB-65 score could better identify patients with COVID-19 at risk for IRVS than the qSOFA score. The CRB score contains the same three clinical parameters used in qSOFA score (confusion, respiratory rate, and blood pressure). However, the thresholds for tachypnea and hypotension in CRB were stricter than the qSOFA score (respiratory rate ≥ 30/min in CRB vs. ≥ 22/min in qSOFA; blood pressure: systolic blood pressure ≤ 100 mmHg in qSOFA vs. < 90 mmHgsys or ≤ 60 mmHgdias in CRB). It seems that qSOFA is more accurate than the CRB score for predicting IRVS. However, in this study, the AUC values of CRB and qSOFA scores were comparable without statistically significant differences. After including the parameter of age, the CRB-65 score performed better than the qSOFA score in predicting requirement of IRVS. As age ≥ 65 years was included in the CRB-65 score, it provided additional predictive performance compared with the CRB score. This result was supported by previous reports, which showed that age was an independent risk factor for mortality in patients with COVID-19. , The CRB-65 score has been reported to have a similar predictive performance to that of the CURB-65 and PSI scores in predicting the severity of CAP.7, 8, 9 In our study, the CRB-65 and CURB-65 scores also had a similar prognostic value in predicting the receipt of IRVS. The CRB-65 score makes it easy to assess the severity of COVID-19 without the limit of laboratory data for blood urea nitrogen especially in the pandemic of COVID-19, thereby allowing earlier triage decisions. In conclusion, the CRB-65 score could better identify patients with COVID-19 at risk for IRVS than the qSOFA score. The CRB-65 may be a useful score tool for COVID-19 because of its simplicity in application especially in emergent and complicated conditions.

Declaration of Competing Interest

The authors declare that they have no competing interests.
  9 in total

Review 1.  Severity assessment tools for predicting mortality in hospitalised patients with community-acquired pneumonia. Systematic review and meta-analysis.

Authors:  James D Chalmers; Aran Singanayagam; Ahsan R Akram; Pallavi Mandal; Philip M Short; Gourab Choudhury; Victoria Wood; Adam T Hill
Journal:  Thorax       Date:  2010-08-20       Impact factor: 9.139

2.  ACP Journal Club. Review: CURB65, CRB65, and Pneumonia Severity Index similarly predict mortality in community-acquired pneumonia.

Authors:  Andrew Morris
Journal:  Ann Intern Med       Date:  2011-04-19       Impact factor: 25.391

3.  Lactate dehydrogenase as a prognostic marker of renal transplant recipients with severe community-acquired pneumonia: a 10-year retrospective study.

Authors:  Ying Su; Min-Jie Ju; Jie-Fei Ma; Guo-Wei Tu; Hong-Yu He; Zhun-Yong Gu; Yuan-Lin Song; Jing Zhang; Zhe Luo
Journal:  Ann Transl Med       Date:  2019-11

4.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.

Authors:  Nanshan Chen; Min Zhou; Xuan Dong; Jieming Qu; Fengyun Gong; Yang Han; Yang Qiu; Jingli Wang; Ying Liu; Yuan Wei; Jia'an Xia; Ting Yu; Xinxin Zhang; Li Zhang
Journal:  Lancet       Date:  2020-01-30       Impact factor: 79.321

Review 5.  Current epidemiological and clinical features of COVID-19; a global perspective from China.

Authors:  Huilan Tu; Sheng Tu; Shiqi Gao; Anwen Shao; Jifang Sheng
Journal:  J Infect       Date:  2020-04-18       Impact factor: 38.637

6.  Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients.

Authors:  Kai Liu; Ying Chen; Ruzheng Lin; Kunyuan Han
Journal:  J Infect       Date:  2020-03-27       Impact factor: 6.072

7.  Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis.

Authors:  Leiwen Fu; Bingyi Wang; Tanwei Yuan; Xiaoting Chen; Yunlong Ao; Thomas Fitzpatrick; Peiyang Li; Yiguo Zhou; Yi-Fan Lin; Qibin Duan; Ganfeng Luo; Song Fan; Yong Lu; Anping Feng; Yuewei Zhan; Bowen Liang; Weiping Cai; Lin Zhang; Xiangjun Du; Linghua Li; Yuelong Shu; Huachun Zou
Journal:  J Infect       Date:  2020-04-10       Impact factor: 6.072

8.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.

Authors:  Fei Zhou; Ting Yu; Ronghui Du; Guohui Fan; Ying Liu; Zhibo Liu; Jie Xiang; Yeming Wang; Bin Song; Xiaoying Gu; Lulu Guan; Yuan Wei; Hui Li; Xudong Wu; Jiuyang Xu; Shengjin Tu; Yi Zhang; Hua Chen; Bin Cao
Journal:  Lancet       Date:  2020-03-11       Impact factor: 79.321

9.  Clinical progression of patients with COVID-19 in Shanghai, China.

Authors:  Jun Chen; Tangkai Qi; Li Liu; Yun Ling; Zhiping Qian; Tao Li; Feng Li; Qingnian Xu; Yuyi Zhang; Shuibao Xu; Zhigang Song; Yigang Zeng; Yinzhong Shen; Yuxin Shi; Tongyu Zhu; Hongzhou Lu
Journal:  J Infect       Date:  2020-03-19       Impact factor: 6.072

  9 in total
  15 in total

1.  CURB-65 as a predictor of 30-day mortality in patients hospitalized with COVID-19 in Ecuador: COVID-EC study.

Authors:  J Carriel; R Muñoz-Jaramillo; O Bolaños-Ladinez; F Heredia-Villacreses; J Menéndez-Sanchón; J Martin-Delgado
Journal:  Rev Clin Esp (Barc)       Date:  2021-04-30

2.  [CURB-65 as a predictor of 30-day mortality in patients hospitalized with COVID-19 in Ecuador: COVID-EC study].

Authors:  J Carriel; R Muñoz-Jaramillo; O Bolaños-Ladinez; F Heredia-Villacreses; J Menéndez-Sanchón; J Martin-Delgado
Journal:  Rev Clin Esp       Date:  2020-10-22       Impact factor: 1.556

3.  Stratifying Deterioration Risk by Acuity at Admission Offers Triage Insights for Coronavirus Disease 2019 Patients.

Authors:  Joseph Beals; Jaime J Barnes; Daniel J Durand; Joan M Rimar; Thomas J Donohue; S Mahfuz Hoq; Kathy W Belk; Alpesh N Amin; Michael J Rothman
Journal:  Crit Care Explor       Date:  2021-04-05

4.  An Early Warning Score to predict ICU admission in COVID-19 positive patients.

Authors:  Sylvain Meylan; Rachid Akrour; Jean Regina; Pierre-Alexandre Bart; Fabrice Dami; Thierry Calandra
Journal:  J Infect       Date:  2020-05-28       Impact factor: 6.072

Review 5.  Clinical Characteristics, Treatment, and Outcomes of Critically Ill Patients With COVID-19: A Scoping Review.

Authors:  Chanyan Huang; Jalal Soleimani; Svetlana Herasevich; Yuliya Pinevich; Kelly M Pennington; Yue Dong; Brian W Pickering; Amelia K Barwise
Journal:  Mayo Clin Proc       Date:  2020-10-26       Impact factor: 7.616

6.  The association of lung ultrasound images with COVID-19 infection in an emergency room cohort.

Authors:  S Bar; A Lecourtois; M Diouf; E Goldberg; C Bourbon; E Arnaud; L Domisse; H Dupont; P Gosset
Journal:  Anaesthesia       Date:  2020-07-01       Impact factor: 12.893

7.  Asthma in COVID-19 patients: An extra chain fitting around the neck?

Authors:  Mohammad H Hussein; Eman A Toraih; Abdallah S Attia; Nicholas Burley; Allen D Zhang; Jackson Roos; August Houghton; Nedum Aniemeka; Mahmoud Omar; Mohamed Aboueisha; Mohamed A Shama; Juan Duchesne; Emad Kandil
Journal:  Respir Med       Date:  2020-11-11       Impact factor: 3.415

8.  Prediction of respiratory decompensation in Covid-19 patients using machine learning: The READY trial.

Authors:  Hoyt Burdick; Carson Lam; Samson Mataraso; Anna Siefkas; Gregory Braden; R Phillip Dellinger; Andrea McCoy; Jean-Louis Vincent; Abigail Green-Saxena; Gina Barnes; Jana Hoffman; Jacob Calvert; Emily Pellegrini; Ritankar Das
Journal:  Comput Biol Med       Date:  2020-08-06       Impact factor: 4.589

9.  Acute kidney injury and kidney replacement therapy in COVID-19: a systematic review and meta-analysis.

Authors:  Edouard L Fu; Roemer J Janse; Ype de Jong; Vera H W van der Endt; Jet Milders; Esmee M van der Willik; Esther N M de Rooij; Olaf M Dekkers; Joris I Rotmans; Merel van Diepen
Journal:  Clin Kidney J       Date:  2020-09-02

10.  Comparing the 4C mortality score for COVID-19 to established scores (CURB65, CRB65, qSOFA, NEWS) for respiratory infection patients.

Authors:  Zoe Wellbelove; Chloe Walsh; Tanaraj Perinpanathan; Patrick Lillie; Gavin Barlow
Journal:  J Infect       Date:  2020-10-25       Impact factor: 6.072

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.